According to CNBC, Novo Nordisk has released the full results of a late-stage trial evaluating its Wegovy injection in children aged 6 to under 12 with obesity. The analysis, which included all participating children—including those who discontinued treatment—showed that at 68 weeks, the BMI reduction in the treatment group was an average of 16.2 percentage points greater than that in the placebo group. The trial enrolled a total of 167 children, all of whom received lifestyle interventions such as diet and exercise. These are clinical trial results and should not be construed as regulatory approval for use in this age group; the impact of early intervention on the long-term disease course still requires further study.